JMP Securities Downgrades Marinus Pharma to Market Perform
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has downgraded Marinus Pharma from Market Outperform to Market Perform, indicating a less optimistic view on the company's stock performance.
October 24, 2024 | 6:44 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JMP Securities has downgraded Marinus Pharma from Market Outperform to Market Perform, suggesting a less favorable outlook on the stock.
The downgrade by JMP Securities indicates a shift in analyst sentiment from a positive to a more neutral stance. This could lead to a decrease in investor confidence and potentially a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100